CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction

doi:10.21203/rs.3.rs-2362549/v2

Download PDF

Article

CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction

https://doi.org/10.21203/rs.3.rs-2362549/v2

This work is licensed under a CC BY 4.0 License

Journal Publication

published 16 Feb, 2023

Read the published version in Scientific Reports →

You are reading this latest preprint version

Previous study from our lab has revealed a new role of CD47 in regulating adipose tissue function, energy homeostasis and the development of obesity and metabolic disease in CD47 deficient mice. In this study, the therapeutic potential of an antisense oligonucleotide (ASO) targeting to CD47 in obesity and its-associated complications was determined in two obese mouse models (diet induced and genetic models). In diet induced obesity, male C57BL6 mice were fed with high fat (HF) diet to induce obesity and then treated with CD47ASO or control ASO for 8 weeks. In genetic obese mouse model, male six-week old ob/ob mice were treated with ASOs for 9 weeks. We found that CD47ASO treatment reduced HF diet-induced weight gain, decreased fat mass, prevented dyslipidemia, and improved glucose tolerance. These changes were accompanied by reduced inflammation in white adipose tissue and decreased hepatic steatosis. This protection was also seen in CD47ASO treated ob/ob mice. Mechanistically, CD47ASO treatment increased mice physical activity and energy expenditure, contributing to weight loss and improved metabolic outcomes in obese mice. Collectively, these findings suggest that CD47ASO might serve as a new treatment option for obesity and its-associated metabolic complications.

Biological sciences/Drug discovery

Biological sciences/Physiology

Health sciences/Diseases

CD47

obesity

antisense oligonucleotide

metabolism

CD47 is an integral glycoprotein cell receptor with a molecular weight of 45-55 kDa ^1,2. It is widely expressed at lower levels by most healthy cells throughout the body ^3,4. Many well-established functions (e.g. immunity, self-recognition, cellular adhesion, and vascular tone) are dependent on the ligand or partner receptor associated with CD47 ^2,5-10. CD47 has been shown to couple to heterotrimeric G_iα and inhibits adenylyl cyclase and then cAMP signaling ^8,9,11. CD47 also inhibits soluble guanylyl cyclase activity to suppress cGMP signaling ^2,10. Both of cAMP and cGMP signaling pathways regulate adipocyte function and impact metabolic health. Accordingly, we have revealed a novel role for CD47 in regulating adipocyte function and its contribution to diet or aging-related obesity and metabolic disorders ^12-14.

Our previous studies showed that genetic deletion (global) of CD47 protected young adult mice from high fat diet-induced obesity by displaying decreased weight gain and reduced adiposity, reduced adipose tissue inflammation, and improved glucose tolerance and insulin sensitivity. This protection is associated with increased brown fat activation, increased lipid utilization and energy expenditure ^12,13. In addition to protecting mice from diet-induced obesity, genetic deletion of CD47 also protects mice from natural aging-associated obesity and glucose intolerance ^14-16. Under normal chow diet conditions, old male CD47 deficient mice had reduced visceral fat mass and improved glucose tolerance. These mice also had increased energy expenditure and better cold tolerance, accompanied by increased white adipose tissue browning and brown adipose tissue (BAT) activity. Collectively, these studies support that CD47 might be a potential target for metabolic disorders of obesity. Thus, in this study, the therapeutic effect of CD47 antisense oligonucleotides (ASO) on obesity and its associated metabolic dysfunction was determined in two obese mouse models (high fat diet induced obesity or genetic obesity models).

Interestingly, in this study, CD47ASO treatment did not stimulate white fat browning or brown fat activity in obese mice at the current dosage. Instead, CD47ASO treatment increased mice physical activity and energy expenditure. It also reduced inflammation in white adipose tissue. All of these effects contribute to the weight loss and improved metabolic outcomes as seen from CD47ASO treated mice.

CD47ASO treatment reduced body weight, adiposity, plasma lipid levels and improved glucose tolerance and fatty liver disease in mice with established obesity

To test the therapeutic effect of CD47ASO on obesity and its-associated metabolic dysfunction, we utilized two obese mouse model in this study. One is the high fat diet (60% fat) induced obesity mouse model (DIO model), a well-established obese mouse model in the field. After 6 weeks of HF diet feeding, male C57BL6 mice developed obesity and glucose intolerance (Fig. S1). CD47ASO or control ASO were then administered into these obese mice for 8 weeks with continuous HF feeding (Fig. 1A). Saline group was also included to examine the non-specific effect that might be induced by control ASO. As shown in Fig. 1B-C, CD47 ASO efficiently knockdown CD47 in metabolic tissues such as liver, skeletal muscle or fat tissues. CD47ASO treatment significantly reduced HF diet induced weight gain starting after 4 weeks of CD47 ASO treatment. Control ASO treatment did not induce weight loss as compared to saline group (Fig. 1D). Fat mass was also significantly reduced, but lean mass was increased in CD47ASO treated mice group (Fig. 1E). The weight loss effect was also confirmed by using two additional CD47ASOs (targeting to different sequence of mouse CD47) (Fig. S2). Plasma lipid levels including triglyceride and cholesterol were reduced by CD47ASO treatment (Fig. 2A). Plasma insulin levels were comparable among all groups (Fig. 2B). However, glucose tolerance was improved in CD47ASO treated mice (Fig. 2C). In addition, CD47ASO treatment reduced hepatic steatosis as demonstrated by reduced liver Oil Red O staining and liver triglyceride measurement (Fig. 3A-B), which was associated with reduced expression of lipid synthesis genes including FAS, ACC and SCD1 (Fig. 3C). Accordingly, plasma ALT and AST levels were reduced in CD47ASO treated mice (Fig. 3D).

In addition to DIO mouse model, genetic obese mouse model (ob/ob) mice were also used in the study. Six-week old male ob/ob mice received saline, control ASO, and CD47ASO treatment for 9 weeks. We found that ob/ob mice showed significant weight loss after 5 weeks of CD47ASO treatment; while control ASO treatment did not induce mice weight loss. CD47ASO treated ob/ob mice displayed reduced adiposity, accompanied with improved glucose tolerance and fatty liver disease as compared to control ASO group (Fig. S3). Together, by utilization of two established obesity mouse models, our data demonstrated that CD47ASO treatment induced obese mice to undergo weight loss and improved blood glucose and lipid homeostasis.

CD47 ASO treatment reduced inflammation in white adipose tissue in mice with established obesity.

To determine the involved mechanisms of CD47ASO mediated weight loss and improved glucose tolerance, we analyzed epidydimal white fat tissue (eWAT). As shown in Fig. 4A, eWAT from CD47ASO treated mice had smaller size of adipocytes. Further qPCR analysis of eWAT showed that CD47ASO treatment increased expression of lipolysis genes (e.g. ATGL) (Fig. 4B), which was accompanied by increased cAMP levels in EAT (Fig. 4C). This suggests that increased lipolysis of eWAT may contribute to the reduced adiposity in CD47ASO treated mice. CD47ASO treatment also reduced the expression of mRNA for pro-inflammatory cytokines (e.g. TNF-α and IL-1β) in eWAT (Fig. 4D). Interestingly, F4/80 expression (macrophage marker) was comparable between control ASO and CD47ASO group. Arg1 expression (M2 macrophage marker) was increased; while NOS2 (M1 macrophage marker) was reduced by CD47ASO treatment. This suggests that CD47ASO treatment may induce adipose tissue macrophage phenotype switch from proinflammatory M1 to anti-inflammatory M2. In addition, CD8 expression (a marker for effector T cell) was reduced by CD47ASO treatment. Together, these data suggest that CD47 ASO treatment reduced inflammation in white adipose tissue, partially through regulation of adipose tissue macrophage phenotype and/or T cell subpopulations ^17-19.

CD47 ASO treated mice had increased energy expenditure

To determine how CD47ASO treatment affected energy balance, mouse indirect calorimetry was performed by utilization of Sable Promethion System including in-cage wheels. We found that CD47ASO treated mice had a trend of increased food intake at dark phase (Fig. 5A). RER (VCO₂/VO₂) was comparable between control ASO and CD47 ASO treatment group (Fig. 5C). However, oxygen consumption and energy expenditure were significantly increased by CD47ASO treatment, especially at dark phase demonstrated by analysis of covariance (ANCOVA) between oxygen consumption/energy expenditure and body weight (Fig. 5B and Fig. 5D). Interestingly, CD47ASO treated mice also displayed significantly increased voluntary wheel running distances (Fig. 5E), suggesting increased physical activity. This was accompanied by increased expression of uncoupling protein 2 and 3 (UCP2 and UCP3) in skeletal muscle (Fig. 5F). UCP3 is a member of the mitochondrial anion carrier protein family mainly expressed in skeletal muscle and plays a role in fatty acid oxidation and energy balance ²⁰. Other fatty acid oxidation or fatty acid uptake related genes such as Cpt1β (carnitine palmitoyltransferase 1, located in the outer of mitochondria membrane and an indispensable enzyme of fatty acid oxidation) or CD36 had a trend of increase in skeletal muscle from CD47ASO treated mice. These data support a role of CD47ASO treatment in regulating skeletal muscle functions. This effect might be independent of mitochondria number in skeletal muscle since PCR data showed that mitochondria DNA copy number in skeletal muscle was comparable between control ASO and CD47 ASO groups (Fig. 5G).

In addition to skeletal muscle, beige and brown fat-mediated thermogenesis could also contribute to increased energy expenditure as seen from CD47ASO treated mice. Therefore, the phenotype of inguinal white fat (iWAT) and brown fat tissue (BAT) from CD47ASO treated DIO mice was also examined. As shown in Fig. S4, iWAT from CD47ASO treated mice had smaller size of adipocytes. However, expression of genes related to white fat browning (UCP1), inflammation (IL-1β and TNF-α) or lipolysis (ATGL and HSL) were comparable between control and CD47ASO groups. As for BAT, expression of genes related to brown fat function such as UCP1, PGC1α, CPT1α, et al were not significantly altered by CD47ASO treatment. Moreover, CD47ASO treated mice showed similar cold intolerance as control mice. Collectively, these data suggest that at the current CD47ASO dosage, with moderately downregulated brown fat CD47 levels, brown fat activity was not significantly altered. So, BAT may not contribute to the increased energy expenditure seen from CD47ASO treated mice; while increased physical activity is the main contributor.

In this study, the therapeutic potential of antisense oligonucleotide (ASO) targeting to CD47 in obesity and metabolic disease was determined. We demonstrate that CD47ASO treatment induces weight loss, decreases fat mass, and improves glucose homeostasis and fatty liver disease in two obese mouse models (DIO and ob/ob mice). These metabolic beneficial effects are associated with increased energy expenditure mainly from skeletal muscle and reduced inflammation in white adipose tissue. Our data suggest that CD47ASO might be a new therapeutic option for obesity and its associated metabolic dysfunction.

One finding of this study is that CD47ASO treatment induced obese mice weight loss, which was associated with increased energy utilization. Previously, we showed that CD47 deficiency protected mice from high fat diet induced obesity, which was attributed to the increased energy expenditure driven by brown adipose tissue (BAT) activity ¹³. BAT expends energy through UCP1-mediated uncoupling, resulting in heat production or thermogenesis ^21,22. Therefore, first, we analyzed BAT function in ASOs treated mice. Interestingly, at the current dosage of CD47ASO (i.p. at 25mg/kg, twice a week), BAT activity was not significantly affected. We found that the expression of UCP1, CPT1 (a carnitine palmitoyltransferase 1, the first and rate-limiting step for fatty acid transporting into the mitochondria for utilization ²³), or PGC1α in BAT were not altered by CD47ASO treatment. CD47ASO treated mice also showed similar cold intolerance as control mice. In addition, there was no white fat browning revealed in CD47ASO treated mice. These data suggest that at the current CD47ASO dosage, brown fat-mediated thermogenesis was not altered by CD47ASO treatment and thus BAT may not contribute to the increased energy expenditure as shown in CD47ASO mice. A higher dosage of CD47ASO may need to be tested in the future study.

Next, we determined the contribution of skeletal muscle to increased energy expenditure in CD47ASO treated mice. A previous study showed that CD47 deficient mice had enhanced treadmill endurance and their skeletal muscle had greater number of mitochondria as compared to wild type mice ¹⁶. CD47 also plays a role in regulating aged muscle stem cell regeneration capacity ²⁴. In the current study, we found that CD47ASO treated mice had increased physical activity demonstrated by increased voluntary wheel running distance in metabolic cages. Further analysis of skeletal muscle gene expression profile, we found that CD47ASO treatment did not increase genes related to mitochondria biogenesis (e.g. PGC1 alpha) in skeletal muscle. Consistently, mitochondria DNA copy number in skeletal muscle was comparable between control ASO and CD47 ASO groups. However, the expression of uncoupling proteins UCP2 and UCP3 in skeletal muscle was significantly upregulated in CD47ASO treated mice. UCP2 and UCP3 have high sequence homology to UCP1 ^25,26. Unlike UCP1 in BAT, studies suggest that UCP2 and UCP3 do not mediate thermogenesis ²⁷. UCP2 is expressed in many tissues including skeletal muscle; while UCP3 is predominantly expressed in skeletal muscle in humans and rodents ^25,28 and plays a role in fatty acid oxidation and body metabolism ^27,29 ³⁰. UCP3 also involves in the effect of physical activity on energy expenditure ²⁰. Increasing UCP3 expression in skeletal muscle stimulates proton leak across the inner mitochondrial membrane and increases oxygen consumption in isolated mitochondria ³¹. Also, in vivo data showed that UCP3 in skeletal muscle is able to uncouple respiration from ATP production ^32,33. This process results in lower energy efficiency and possibly increased energy expenditure. Consistently, transgenic mice with overexpression of UCP3 in skeletal muscle were lean ³¹ and insulin sensitive ³⁴. Based on these observations, we speculate that increased expression of UCP3 in skeletal muscle may mediate CD47ASO treatment induced increase in energy expenditure. This warrants further investigation in the future.

CD47 has well-known immune-regulatory functions ^35-39. In this study, the effect of CD47ASO treatment on white adipose tissue inflammation in obese mice was examined. It is well-known that obesity is associated with low-grade chronic inflammation. Visceral adipose tissue has been suggested to be the primary source of cytokine and adipokine release within obesity-associated inflammation. It is marked by the accumulation of macrophages, T cells and other immune cells in adipose tissue, leading to the development of glucose tolerance and insulin resistance ^37,40,41. We found that CD47ASO treatment significantly reduced pro-inflammatory cytokine production in eWAT, which was accompanied by improved whole body glucose tolerance. This CD47ASO-mediated anti-inflammatory effect is not through reducing macrophage infiltration into white adipose tissue rather than switching macrophage phenotype from pro-inflammatory to anti-inflammatory phenotype. In addition to macrophages, it has been shown that CD8+ T cells accumulate in adipose tissue in obese mice and play an important role in adipose tissue inflammation ^41,42. Interestingly, CD47ASO treatment reduced CD8 expression in eWAT, suggesting that CD8+ T cells might be reduced in adipose tissue. Collectively, our data suggest that CD47ASO treatment may regulate both macrophage and T cell function, contributing to the reduced adipose tissue inflammation and improved glucose homeostasis.

In summary, our studies demonstrate that CD47ASO treatment stimulates physical activity, leading to increased energy expenditure and weight loss in obese mice. CD47ASO treatment also reduces obesity- associated metabolic complications including decreased adipose tissue inflammation and hepatosteatosis, and improved glucose tolerance. The results from this study suggest that CD47ASO may serve as a new therapeutic option for obesity and its related comorbidities.

Animals

All the experiments involving mice conformed to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the University of Kentucky Institutional Animal Care and Use Committee (IACUC). The authors compiled with the ARRIVE guidelines. All animals were housed in a pathogen-free environment at 22°C in 14-hour light/ 10-hour dark cycle. Male six-week old C57BL6 mice (The Jackson Laboratory; Bar Harbor, ME) were fed with high fat diet (60% fat) (D12492, Research Diets, Inc, NJ) for 6 weeks to induce obesity and glucose intolerance. These diet-induced obesity (DIO) mice were then divided into three groups (n=5-7 mice/group) and injected twice a week with saline, control ASO (GGCCAATACGCCGTCA) or CD47 ASO (ATTGATTAAGTCTGAG, targeting to mouse CD47) (provided by Ionis Pharmaceuticals, Carlsbad, CA) at a 25mg/kg body weight by i.p. for 8 weeks with continuous high fat diet feeding in all groups. These ASOs are chemically stabilized with constrained ethyl modification in the wings and phosphorothioate linkages ⁴³. At the end of study, mice were anesthetized by intraperitoneal injection of Ketamine (100 mg/kg) combined with Xylazine (10 mg/kg). After blood was drawn and several tissues were harvested, cervical dislocation of mice was performed to ensure their deaths.

Another study was conducted with C57BL6J-Lep^ob/Lep^ob (ob/ob) mice. Five-week old ob/ob mice were purchased from Jackson Laboratories. After one-week acclimation, ob/ob mice were divided into three groups and treated with saline, control ASO and CD47 ASO at 25 mg/kg body weight (i.p) twice a week for 8-9 weeks.

Metabolic analysis

Body weight was measured weekly. At the end of the study, body composition was measured by Echo MRI ¹³. Two weeks prior to the end of study, mice were placed in Sable Promethion system with in-cage running wheels individually for 5 days for measurement of food intake, water intake and indirect calorimetry.

Cold exposure and body temperature measurement

Implantable Programmable Temperature Transponder 300 (IPTT-300, BioMedic Data Systems, Delaware, USA) was interscapularly implanted into mice. After one day of acclimatization, mice were put in 4°C cold room individually without food for 6 hr. Body temperature of the mice was monitored at 0, 1, 2, 3, 4 and 6 hr during cold exposure.

Blood parameter analysis and glucose tolerance test

At the end of study, blood samples were obtained via cardiac puncture. Plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were measured by using ALT and AST assay kit (Connecticut, USA). Blood glucose levels were measured by using glucometer. Plasma insulin levels were measured by using ELISA Kit (Crystal Chem USA, IL). For glucose tolerance test (GTT), mice were fasted 6 hours before intraperitoneal injections of glucose (1 g/kg body weight). Blood glucose concentrations were measured using a glucometer at 0, 15, 30, 60, and 120 minutes post injection.

Lipid Analysis

Plasma total cholesterol and triglyceride, and hepatic cholesterol and triglyceride concentrations were determined enzymatically with Wako kits (Richmond, USA). For analysis of hepatic lipid, approximately 50 mg of liver was placed into 500 μl of chilled Krebs Ringer Phosphate buffer (118 mM NaCl, 5 mM KCl, 13.8 mM CaCl₂, 1.2 mM MgSO₄, 0.016% KH₂PO₄, 0.211% NaHCO₂) and each sample was sonicated for ten times (3 seconds/time).

White adipose tissue cAMP and cGMP measurement

cAMP and cGMP levels in white adipose tissue were measured by using the cAMP and cGMP ELISA kits from R&D Systems (Minneapolis, USA) and Abcam (Boston, USA), respectively. In brief, 100 mg of epididymal adipose tissue was homogenized in 1 ml of 0.1N HCl and the supernatant was collected. The samples were then neutralized with 1N of NaOH or neutralizing reagents provided from the kits. cAMP or cGMP levels in the supernatant were measured and calculated based on the cAMP or cGMP standard curve following the instruction manual.

Western blotting

Liver tissues were homogenized in RIPA buffer (Sigma, St. Louis, MO, USA) plus protease and phosphatase inhibitors (Pierce, Waltham, MA, USA). After concentrations were measured using a BCA Assay (Pierce, Waltham, MA, USA), 30μg protein/well was subjected to SDS-PAGE gel under reducing conditions and transferred onto a nitrocellulose membrane. After blocking, the membrane was incubated with anti-β-actin (1:5000 dilution; Santa Cruz, Dallas, TX, USA) and anti-CD47 (1:1000 dilution; Abcam, Cambridge, MA, USA) at 4°C overnight. After washing, the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies (Jackson Labs, Bar Harbor, ME, USA). The reaction was visualized by using an enhanced chemiluminescence system (Pierce, Waltham, MA, USA).

Tissue Histology

Fat tissues and liver tissues from all groups of animals were fixed in 10% Formalin for 24 hr, embedded in paraffin, sectioned at 5 μm, and stained with hematoxylin and eosin-stain (H&E) by standard method by using the service from COBRE Pathology Core at University of Kentucky. In addition, liver cryo-sections were fixed with 4% PFA and stained with 0.5% Oil red O in 60% isopropyl alcohol. All images were acquired with a Nikon Eclipse 55i.

Real-time quantitative PCR

Total RNA from tissues were extracted using TRIzol Reagent (Thermo Fisher Scientific, Massachusetts, USA). RNA was reverse transcribed to cDNA by the cDNA Synthesis Kit (Quantabio, Massachusetts, USA). Real-time quantitative PCR was performed using a MyiQ Real-time PCR Thermal Cycler (Bio-Rad) with SYBR Green PCR Master Kit (Qiagen, Valencia, CA). Relative mRNA expression was calculated using the MyiQ system software as previous reported ⁴⁴ and normalized to β-actin levels. All primer sequences utilized in this study are found in Table 1.

Statistical analysis

Statistical analysis was performed using Prism 9 (GraphPad Software, San Diego, CA). All data are presented as the mean ± SEM. Statistical significance between two groups was determined using two-tailed Student’s t-test. One-way ANOVA followed by Bonferroni’s multiple comparisons test or 2-way ANOVA followed by Tukey’s multiple comparisons test was applied for multi-group comparisons. P values of less than 0.05 were considered to be significant.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Acknowledgements

We would like to thank Dr. Wendy Katz at University of Kentucky for assisting in mice indirect calorimetry analysis.

Author contributions statement

S.W. designed experiments and wrote the manuscript; T.G, D.L., and E.M. conducted the experiments and analyzed the results; Z.G. and Y.L. reviewed and edited the manuscript. All authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Funding

This work was supported by the Department of Veterans Affairs Merit Review Award (I01BX004252, to SW), the National Institutes of Health (NIH) Grant (DK098176, DK131786, to SW), and an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P30 GM127211.

Kaur, S. et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 286, 14991-15002, doi:10.1074/jbc.M110.179663 (2011).
Soto-Pantoja, D. R., Kaur, S. & Roberts, D. D. CD47 signaling pathways controlling cellular differentiation and responses to stress. Critical reviews in biochemistry and molecular biology 50, 212-230, doi:10.3109/10409238.2015.1014024 (2015).
Oldenborg, P. A. CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and Disease. ISRN hematology 2013, 614619, doi:10.1155/2013/614619 (2013).
Brown, E. J. & Frazier, W. A. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11, 130-135 (2001).
Oldenborg, P. A. et al. Role of CD47 as a marker of self on red blood cells. Science 288, 2051-2054 (2000).
Willingham, S. B. et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A 109, 6662-6667, doi:1121623109 [pii]10.1073/pnas.1121623109 [doi] (2012).
Roberts, D. D. & Isenberg, J. S. CD47 and thrombospondin-1 regulation of mitochondria, metabolism, and diabetes. Am J Physiol Cell Physiol, doi:10.1152/ajpcell.00175.2021 (2021).
Isenberg, J. S. et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 28, 110-119, doi:10.1016/j.matbio.2009.01.002 (2009).
Yao, M., Roberts, D. D. & Isenberg, J. S. Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP. Pharmacological research : the official journal of the Italian Pharmacological Society 63, 13-22, doi:10.1016/j.phrs.2010.10.014 (2011).
Bauer, E. M. et al. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 88, 471-481 (2010).
Frazier, W. A. et al. The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi. J Biol Chem 274, 8554-8560. (1999).
Norman-Burgdolf, H., Li, D., Sullivan, P. & Wang, S. CD47 differentially regulates white and brown fat function. Biol Open 9, doi:10.1242/bio.056747 (2020).
Maimaitiyiming, H., Norman, H., Zhou, Q. & Wang, S. CD47 deficiency protects mice from diet-induced obesity and improves whole body glucose tolerance and insulin sensitivity. Sci Rep 5, 8846, doi:10.1038/srep08846 (2015).
Li, D., Gwag, T. & Wang, S. Absence of CD47 maintains brown fat thermogenic capacity and protects mice from aging-related obesity and metabolic disorder. Biochem Biophys Res Commun 575, 14-19, doi:10.1016/j.bbrc.2021.08.062 (2021).
Ghimire, K. et al. CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and Glucose Homeostasis. Cells 9, doi:10.3390/cells9071695 (2020).
Frazier, E. P. et al. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 30, 154-161, doi:10.1016/j.matbio.2010.12.004 (2011).
Zhu, F. et al. Adipose Tissue-Resident Regulatory T Cells. Advances in experimental medicine and biology 1011, 153-162, doi:10.1007/978-94-024-1170-6_4 (2017).
Nishimura, S. et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15, 914-920, doi:10.1038/nm.1964 (2009).
Wang, Q., Wang, Y. & Xu, D. The roles of T cells in obese adipose tissue inflammation. Adipocyte 10, 435-445 (2021).
Schrauwen, P. & Hesselink, M. Uncoupling protein 3 and physical activity: the role of uncoupling protein 3 in energy metabolism revisited. The Proceedings of the Nutrition Society 62, 635-643, doi:10.1079/pns2003277 (2003).
Cannon, B. & Nedergaard, J. Brown adipose tissue: function and physiological significance. Physiol Rev 84, 277-359 (2004).
Cannon, B. & Nedergaard, J. Studies of thermogenesis and mitochondrial function in adipose tissues. Methods Mol Biol 456, 109-121, doi:10.1007/978-1-59745-245-8_8 (2008).
Schreurs, M., Kuipers, F. & van der Leij, F. R. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obesity reviews : an official journal of the International Association for the Study of Obesity 11, 380-388, doi:10.1111/j.1467-789X.2009.00642.x (2010).
Porpiglia, E. et al. Elevated CD47 is a hallmark of dysfunctional aged muscle stem cells that can be targeted to augment regeneration. Cell Stem Cell, doi:10.1016/j.stem.2022.10.009 (2022).
Vidal-Puig, A., Solanes, G., Grujic, D., Flier, J. S. & Lowell, B. B. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun 235, 79-82, doi:10.1006/bbrc.1997.6740 (1997).
Ledesma, A., de Lacoba, M. G. & Rial, E. The mitochondrial uncoupling proteins. Genome Biol 3, REVIEWS3015 (2002).
Wolf, G. The uncoupling proteins UCP2 and UCP3 in skeletal muscle. Nutr Rev 59, 56-57, doi:10.1111/j.1753-4887.2001.tb06977.x (2001).
Boss, O. et al. Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett 408, 39-42, doi:10.1016/s0014-5793(97)00384-0 (1997).
Schrauwen, P. & Hesselink, M. UCP2 and UCP3 in muscle controlling body metabolism. J Exp Biol 205, 2275-2285, doi:10.1242/jeb.205.15.2275 (2002).
Giralt, M. & Villarroya, F. Mitochondrial Uncoupling and the Regulation of Glucose Homeostasis. Curr Diabetes Rev 13, 386-394, doi:10.2174/1573399812666160217122707 (2017).
Clapham, J. C. et al. Mice overexpressing human uncoupling protein-3 in skeletal muscle are hyperphagic and lean. Nature 406, 415-418, doi:10.1038/35019082 (2000).
Cline, G. W. et al. In vivo effects of uncoupling protein-3 gene disruption on mitochondrial energy metabolism. J Biol Chem 276, 20240-20244, doi:10.1074/jbc.M102540200 (2001).
Codella, R. et al. Overexpression of UCP3 decreases mitochondrial efficiency in mouse skeletal muscle in vivo. FEBS Lett, doi:10.1002/1873-3468.14494 (2022).
Choi, C. S. et al. Overexpression of uncoupling protein 3 in skeletal muscle protects against fat-induced insulin resistance. J Clin Invest 117, 1995-2003, doi:10.1172/jci13579 (2007).
Hayat, S. M. G. et al. CD47: role in the immune system and application to cancer therapy. Cell Oncol (Dordr) 43, 19-30, doi:10.1007/s13402-019-00469-5 (2020).
Logtenberg, M. E. W., Scheeren, F. A. & Schumacher, T. N. The CD47-SIRPα Immune Checkpoint. Immunity 52, 742-752 (2020).
Kawai, T., Autieri, M. V. & Scalia, R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol 320, C375-C391 (2021).
Tseng, D. et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A 110, 11103-11108, doi:10.1073/pnas.1305569110 (2013).
Cham, L. B. et al. Immunotherapeutic Blockade of CD47 Inhibitory Signaling Enhances Innate and Adaptive Immune Responses to Viral Infection. Cell reports 31, 107494, doi:10.1016/j.celrep.2020.03.058 (2020).
Wajchenberg, B. L. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocrine reviews 21, 697-738, doi:10.1210/edrv.21.6.0415 (2000).
Kiran, S., Kumar, V., Murphy, E. A., Enos, R. T. & Singh, U. P. High Fat Diet-Induced CD8(+) T Cells in Adipose Tissue Mediate Macrophages to Sustain Low-Grade Chronic Inflammation. Frontiers in immunology 12, 680944 (2021).
Wang, Q. & Wu, H. T Cells in Adipose Tissue: Critical Players in Immunometabolism. Frontiers in immunology 9, 2509 (2018).
Seth, P. P. et al. Short antisense oligonucleotides with novel 2'-4' conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals. Journal of medicinal chemistry 52, 10-13, doi:10.1021/jm801294h (2009).
Li, Y., Tong, X., Rumala, C., Clemons, K. & Wang, S. Thrombospondin1 deficiency reduces obesity-associated inflammation and improves insulin sensitivity in a diet-induced obese mouse model. PLoS One 6, e26656 (2011).

Table 1 is available in the Supplementary Files section.

No competing interests reported.

Download PDF

Journal Publication

published 16 Feb, 2023

Read the published version in Scientific Reports →

Editorial decision: Accepted
14 Feb, 2023
Reviews received at journal
12 Feb, 2023
Reviewers agreed at journal
12 Feb, 2023
Reviews received at journal
10 Feb, 2023
Reviewers agreed at journal
09 Feb, 2023
Reviewers invited by journal
09 Feb, 2023
Submission checks completed at journal
06 Feb, 2023
First submitted to journal
31 Jan, 2023

You are reading this latest preprint version

CD47 antisense oligonucleotide treatment attenuates obesity and its-associated metabolic dysfunction

Status:

Journal Publication

Version 2

Abstract

Figures

Introduction

Results

Discussion

Methods

Declarations

References

table

Additional Declarations

Supplementary Files

Status:

Journal Publication

Version 2